Dr Paul Marks place on Cellceutix SAB
This article was originally published in Scrip
Cellceutix, a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, has appointed Dr Paul Marks to its scientific advisory board. Dr Marks served as president and CEO of Memorial Sloan-Kettering Cancer Center from 1980-1999, and remains a part of MSKCC as president emeritus and a member of the Sloan-Kettering Institute. Dr Marks joins Cellceutix just as the company has filed foreign patent applications relating to its anti-cancer compound Kevetrin for the treatment of cancer.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.